{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:26:04Z","timestamp":1791815164365,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ymthe.2024.01.009","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T21:21:38Z","timestamp":1704835298000},"page":"609-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["\u03b1-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1\/2 trial"],"prefix":"10.1016","volume":"32","author":[{"given":"Paul","family":"Harmatz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Kira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Takasao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairei","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Hirato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-8643","authenticated-orcid":false,"given":"Yuji","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.01.009_bib1","series-title":"Mucopolysaccharidoses Update","first-page":"143","article-title":"Mucopolysaccharidosis type I: Clinical features, biochemistry, diagnosis, genetics, and treatment","author":"Munoz-Rojas MV","year":"2018"},{"key":"10.1016\/j.ymthe.2024.01.009_bib2","series-title":"Mucopolysaccharidosis Type I (MPS I)","author":"Tylki-Szymanska","year":"2022"},{"key":"10.1016\/j.ymthe.2024.01.009_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2024.01.009_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/gim.2014.25","article-title":"The natural history of MPS I: global perspectives from the MPS I Registry","volume":"16","author":"Beck","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2024.01.009_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2024.01.009_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.895511","article-title":"Hematopoietic Stem Cell Transplantation for Neurological Disorders: A Focus on Inborn Errors of Metabolism","volume":"16","author":"de Vasconcelos","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2024.01.009_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020189","article-title":"Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement","volume":"11","author":"Hampe","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2024.01.009_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2017.5","article-title":"Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome","volume":"52","author":"Lum","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.ymthe.2024.01.009_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"de Ru","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2024.01.009_bib10","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s11011-021-00893-3","article-title":"Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid","volume":"37","author":"Sato","year":"2022","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.ymthe.2024.01.009_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061240","article-title":"Treatment of Neuronopathic Mucopolysaccharidoses with Blood\u2013Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis","volume":"14","author":"Sonoda","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2024.01.009_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.omtm.2023.05.010","article-title":"Enzyme replacement with transferrin receptor-targeted alpha-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice","volume":"29","author":"Kida","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.01.009_bib13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.009_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020400","article-title":"Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses","volume":"21","author":"Sato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.009_bib15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1\/2 Trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.009_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A Phase 2\/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.009_bib17","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","article-title":"Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil","volume":"29","author":"Giugliani","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.009_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010938","article-title":"Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.009_bib19","series-title":"Phase I\/II Study of JR-171 \u33cc Patients with Mucopolysaccharidosis Type I","year":"2022"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:12:27Z","timestamp":1761502347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1525001624000091"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.009","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b1-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1\/2 trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}]}}